Rivaroxaban: the risk of development of undesirable reactions of interaction


Cite item

Full Text

Abstract

The anticoagulants in peroral form are generally applied under various diseases with increased susceptibility to thrombus formation. Nowadays, the selective anticoagulants influencing in a inhibition way only one of factors of blood coagulation system are used more extensively in the clinical practice. Rivaroxaban is one of such pharmaceuticals. Rivaroxaban regulates formation of thrombin at the expense of blocking of factor Xa action without direct impact on thrombin. The combined application of Rivaroxaban with inhibitors - CYP3A4 and P-glycoprotein increases concentration of pharmaceutical in blood plasma. This occurrence significantly intensifies its pharmacodynamic effect and considerably increases risk of development of massive bleedings and other possible side-effects. Rivaroxaban is metabolized with CYP3A4 and P-glycoprotein hence the most obvious manifestations of interaction reactions were detected under combined application with pharmaceuticals affecting both of these structures.

About the authors

A. S Kazakov

The Research center of expertise of facilities of medical application of the Ministry of Health of Russia

Email: a.kazakov15@gmail.com

A. V Astakhova

The Research center of expertise of facilities of medical application of the Ministry of Health of Russia

V. K Lepakhin

The Research center of expertise of facilities of medical application of the Ministry of Health of Russia

References

  1. Fox K.A., Cokkinos D.V, Deckers J. et al. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur. Heart J. 2000; 21: 1440-9.
  2. Fox K.A., Goodman S.G., Klein W. et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 2002; 23: 1177-89.
  3. Hasdai D., Behar S., Wallentin L. et al. A prospective survey of the characteristics, treatments and outcomes in patients with acute coronary syndromes in Europe and Mediterranean basin; the Euro Heart Survey of Acute Coranary Syndromes (Euro Heart Survey ACS). Eur. Heart J. 2002; 23: 1190-201.
  4. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Program. Eur. Heart J. 2001; 22: 554-72.
  5. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey of ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J. 2005; 26: 2422-34.
  6. van Veldhuisen D.J., Charlesworth A., Crijns H.J. et al. Differences in drug treatment of chronic heart failure between European contries. Eur. Heart J. 1999; 20: 666-72.
  7. Giuntini C., Di Ricco G., Marini C. et al. Pulmonary embolism: epidemiology. Chest. 1995; 107: 3S-9S.
  8. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. Second report of session 2004-5. http://www.dh.gov.uk/en/Publicationsandstatistics/Letter-sandcirculars/Dearcolleagueletters/DH_4116227. Accessed October 2007
  9. Cohen A.T., Agnelli G., Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 2007; 98: 756-64.
  10. Fitzmaurice D.A., Murray E. Thromboprophylaxis for adults in hospital. Br. Med. J. 2007; 334: 1017-8.
  11. Cushman M., Tsai A.W., White R.H. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am. J. Med. 2004; 117: 19-25.
  12. Heit J.A., Melton L.J., 3rd, Lohse C.M. et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin. Proc. 2001; 76: 1102-10.
  13. Silverstein M.D., Heit J.A., Mohr D.N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 1998; 158: 585-93.
  14. Heit J.A., Cohen A.T., Anderson F.A., Jr. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts). 2005; 106: abstr. 910.
  15. Белов М.В., Соловьев Е.Я., Метельков С.А., Туровник А.С. Использование Ривароксабана - нового прямого ингибитора фактора Xa у травматологических больных. Современная травматология и ортопедия. 2012; 3.
  16. Сулимов В.А. Профилактика венозных тромбоэмболий. М.: ГЭОТАР -Медиа; 2009.
  17. Cipolle G.P., Wojcik R., Seislove E. еt al. The role of surveillance duplex scanningin preventing venous tromboembolism in trauma patient. J. Trauma. 2002; 52: 453-62.
  18. Clagett G.P., Reisch J.S. Prevention of venous trombolism in general surgical patient: result of meta-analysis. Ann. Surg. 1988; 208: R227-40.
  19. Мурылёв В., Елизаров П., Рукин Я., Казарян Г., Музыченков А., Калинский Б. Ксарелто в профилактике тромбоэмболии у пациентов с венозной патологией при эндопротезировании. Врач. 2011; 12: 1-4.
  20. Edelsberg J., Ollendorf D., Oster G. Venous thromboembolism followi ng major orthopedic surgery: review of epidemiology and economics. Am. J. Health Syst. Pharm. 2001; 58 (Suppl. 2): S4-13.
  21. Heit J.A., Silverstein M.D., Mohr D.N. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch. Intern. Med. 1999; 159: 445-53.
  22. http://medi.ru/doc/261000.htm
  23. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? J. Thromb. Haemost. 2003; 1: 1504-14.
  24. http://grls.rosminzdrav.ru/
  25. Horn J.R., Hansten P.D. Rivaroxaban: a new oral anticoagulant. Pharmacy Times. 2012; 78 (2).
  26. Xarelto (rivaroxaban) tablets label. www.accessdata.fda.gov/ drugsatfda_docs/label/2011/202439s001lbl.pdf
  27. Kubitza D., Becka M., Mueck W. et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 2010; 70: 703-12.
  28. FDA Medication Guide rivaroxaban. http://www.fda.gov/downloads/ Drugs/DrugSafety/UCM280333.pdf
  29. Xarelto [package insert]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc; 2011.
  30. Annex 1 Summary of Product Characteristics Rivaroxaban. http://www.xarelto.com/html/downloads/Xarelto_Summary_of_ Product_ Characteristics_30Sept2008.pdf
  31. Drug Approval Package Xarelto (Rivaroxaban). http://www. accessdata.fda.gov/drugsatfda_docs/nda/2011/202439toc.cfm
  32. Kubitza D., Becka M., Mueck W. et al. Rivaroxaban (BAY 597939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol. 2007; 63: 469-76.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies